UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | June 23, 2011 |
SeraCare Life Sciences, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 1-34105 | 33-0056054 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 37 Birch Street, Milford, Massachusetts | | 01757 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | (508) 244-6400 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On June 23, 2011, SeraCare Life Sciences, Inc., (the "Company") announced the receipt of an unsolicited offer from MSMB Capital proposing to purchase all of the outstanding shares of the Company for $4.25 per share. It is anticipated that the Company's Board of Directors will review the proposal in due course.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press release, dated June 23, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | SeraCare Life Sciences, Inc. |
| | | | | |
| June 23, 2011 | | By: | | /s/ Gregory A. Gould
|
| | | | |
|
| | | | | Name: Gregory A. Gould |
| | | | | Title: Chief Financial Officer, Secretary and Treasurer |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press release, dated June 23, 2011. |
